Low-graphic news index |
Saturday, February 23, 2013 - Page updated at 01:31 a.m.
Blaze Bioscience raises $8.5M
By Seattle Times business staff
Blaze Bioscience, a Seattle biotechnology company, said it has completed an $8.5 million financing and will use the money for early clinical trials of a product for visualizing cancer tumors during surgery.
The company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors; the goal is to highlight cancer cells so they can be completely removed.
Blaze, a spin-off using discoveries at the Fred Hutchinson Cancer Research Center, has now attracted $9.8 million since its founding in 2010.
Low-graphic news index
Graphic-enabled home page